GenSight Biologics announced that two oral presentations will be presented at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) taking place virtually on October 19-22, 2021.

Details for the oral presentations are as follows:


LUMEVOQ® (GS010; lenadogene nolparvovec), for the treatment of Leber Hereditary Optic Neuropathy (LHON)

The phase III REFLECT trial: Efficacy and safety of bilateral gene therapy for Leber Hereditary Optic Neuropathy (LHON) will be presented by Patrick Yu Wai Man, MD, University of Cambridge, United Kingdom and Investigator in the REFLECT trial.

  • Oral Presentation
  • Session 1a: CNS & Sensory I
  • Abstract Number: OR3
  • Tuesday, October 19, 2021, 6:30 – 6:45 pm CET


GS030 – Optogenetics in Retinitis Pigmentosa (RP)

 Partial recovery of visual function in a blind patient after optogenetic therapy for non-syndromic Retinitis Pigmentosa will be presented by José-Alain Sahel, MD, University of Pittsburgh School of Medicine, United States and Co-founder of GenSight Biologics.

  • Oral Presentation
  • Session 3: Towards innovative gene therapy trials
  • Abstract Number: INV36
  • Wednesday, October 20, 2021, 7:15 – 7:45 pm CET